- May provide short, lighter periods1,3
- Mean duration of withdrawal bleeding was <2 days per cycle
- Patient-reported intensity of withdrawal bleeding was lighter than normal
- Incidence of amenorrhea increased over the course of the study; from 32% in Cycle 1 to 49% in
Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. Counsel patients that amenorrhea may occur. Rule out pregnancy in the event of amenorrhea in two or more consecutive cycles.
any interval with no reported bleeding or spotting.
Lo Loestrin Fe is the only available ultra-low-dose option with 10 mcg of daily estrogen that provides effective pregnancy prevention with an acceptable bleeding profile.1,3
|†||Maximum savings limits apply; patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please click here for Program Terms, Conditions, and Eligibility Criteria.|